12
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Epidemiology and impact of chronic bronchitis in chronic obstructive pulmonary disease

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Research on the association between chronic bronchitis and chronic obstructive pulmonary disease (COPD) exacerbations has led to discordant results. Furthermore, the impact of chronic bronchitis on mortality in COPD subjects is unclear.

          Within the Rotterdam Study, a population-based cohort study of subjects aged ≥45 years, chronic bronchitis was defined as having a productive cough for ≥3 months per year for two consecutive years. Linear, logistic regression and Cox proportional hazard models were adjusted for age, sex and pack-years.

          Out of 972 included COPD subjects, 752 had no chronic phlegm production (CB ) and 220 had chronic phlegm production, of whom 172 met the definition of chronic bronchitis (CB +). CB + subjects were older, more frequently current smokers and had more pack-years than CB subjects. During a median 6.5 years of follow-up, CB + subjects had greater decline in lung function (−38 mL·year −1, 95% CI −61.7–−14.6; p=0.024). CB + subjects had an increased risk of frequent exacerbations (OR 4.0, 95% CI 2.7–5.9; p<0.001). In females, survival was significantly worse in CB + subjects compared to CB subjects. Regarding cause-specific mortality, CB + subjects had an increased risk of respiratory mortality (hazard ratio 2.16, 95% CI 1.12–4.17; p=0.002).

          COPD subjects with chronic bronchitis have an increased risk of exacerbations and respiratory mortality compared to COPD subjects without chronic phlegm production.

          Abstract

          Chronic bronchitis increases the risk of exacerbations and mortality among patients with COPD http://ow.ly/o1fq30bFf9Q

          Related collections

          Most cited references25

          • Record: found
          • Abstract: found
          • Article: not found

          Susceptibility to exacerbation in chronic obstructive pulmonary disease.

          Although we know that exacerbations are key events in chronic obstructive pulmonary disease (COPD), our understanding of their frequency, determinants, and effects is incomplete. In a large observational cohort, we tested the hypothesis that there is a frequent-exacerbation phenotype of COPD that is independent of disease severity. We analyzed the frequency and associations of exacerbation in 2138 patients enrolled in the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study. Exacerbations were defined as events that led a care provider to prescribe antibiotics or corticosteroids (or both) or that led to hospitalization (severe exacerbations). Exacerbation frequency was observed over a period of 3 years. Exacerbations became more frequent (and more severe) as the severity of COPD increased; exacerbation rates in the first year of follow-up were 0.85 per person for patients with stage 2 COPD (with stage defined in accordance with Global Initiative for Chronic Obstructive Lung Disease [GOLD] stages), 1.34 for patients with stage 3, and 2.00 for patients with stage 4. Overall, 22% of patients with stage 2 disease, 33% with stage 3, and 47% with stage 4 had frequent exacerbations (two or more in the first year of follow-up). The single best predictor of exacerbations, across all GOLD stages, was a history of exacerbations. The frequent-exacerbation phenotype appeared to be relatively stable over a period of 3 years and could be predicted on the basis of the patient's recall of previous treated events. In addition to its association with more severe disease and prior exacerbations, the phenotype was independently associated with a history of gastroesophageal reflux or heartburn, poorer quality of life, and elevated white-cell count. Although exacerbations become more frequent and more severe as COPD progresses, the rate at which they occur appears to reflect an independent susceptibility phenotype. This has implications for the targeting of exacerbation-prevention strategies across the spectrum of disease severity. (Funded by GlaxoSmithKline; ClinicalTrials.gov number, NCT00292552.)
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper.

            W MacNee, , B Celli (2004)
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Chronic bronchitis and chronic obstructive pulmonary disease.

              Chronic bronchitis (CB) is a common but variable phenomenon in chronic obstructive pulmonary disease (COPD). It has numerous clinical consequences, including an accelerated decline in lung function, greater risk of the development of airflow obstruction in smokers, a predisposition to lower respiratory tract infection, higher exacerbation frequency, and worse overall mortality. CB is caused by overproduction and hypersecretion of mucus by goblet cells, which leads to worsening airflow obstruction by luminal obstruction of small airways, epithelial remodeling, and alteration of airway surface tension predisposing to collapse. Despite its clinical sequelae, little is known about the pathophysiology of CB and goblet cell hyperplasia in COPD, and treatment options are limited. In addition, it is becoming increasingly apparent that in the classic COPD spectrum, with emphysema on one end and CB on the other, most patients lie somewhere in the middle. It is known now that many patients with severe emphysema can develop CB, and small airway pathology has been linked to worse clinical outcomes, such as increased mortality and lesser improvement in lung function after lung volume reduction surgery. However, in recent years, a greater understanding of the importance of CB as a phenotype to identify patients with a beneficial response to therapy has been described. Herein we review the epidemiology of CB, the evidence behind its clinical consequences, the current understanding of the pathophysiology of goblet cell hyperplasia in COPD, and current therapies for CB.
                Bookmark

                Author and article information

                Journal
                Eur Respir J
                Eur. Respir. J
                ERJ
                erj
                The European Respiratory Journal
                European Respiratory Society
                0903-1936
                1399-3003
                August 2017
                10 August 2017
                : 50
                : 2
                : 1602470
                Affiliations
                [1 ]Dept of Respiratory Medicine, Ghent University and Ghent University Hospital, Ghent, Belgium
                [2 ]Dept of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands
                [3 ]Laboratory of Immunoregulation and Mucosal Immunology, VIB-UGent Center for Inflammation Research, Ghent, Belgium
                [4 ]Member of the Netherlands Consortium on Healthy Aging (NCHA)
                [5 ]Inspectorate of Healthcare, The Hague, The Netherlands
                [6 ]Dept of Respiratory Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
                Author notes
                Guy G. Brusselle; Dept of Epidemiology, Erasmus MC, PO Box 2040; 3000 CA Rotterdam, the Netherlands. E-mail: g.brusselle@ 123456erasmusmc.nl
                Article
                ERJ-02470-2016
                10.1183/13993003.02470-2016
                5593375
                28798087
                bbb56402-528a-4087-870f-186e11dde862
                Copyright ©ERS 2017

                This ERJ Open article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

                History
                : 16 December 2016
                : 02 May 2017
                Funding
                Funded by: Fonds Wetenschappelijk Onderzoek http://doi.org/10.13039/501100003130
                Award ID: G035014N
                Award ID: G089712N
                Funded by: Bijzonder Onderzoeksfonds http://doi.org/10.13039/501100007229
                Award ID: 01G02714
                Categories
                Original Articles
                COPD
                1

                Respiratory medicine
                Respiratory medicine

                Comments

                Comment on this article